Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI154909

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Wenqing Li, Robert Shenkar, Mathew R. Detter, Thomas Moore, Christian Benavides, Rhonda Lightle, Romuald Girard, Nicholas Hobson, Ying Cao, Yan Li, Erin Griffin, Carol Gallione, Joseph M. Zabramski, Mark H. Ginsberg, Douglas A. Marchuk, and Issam A. Awad

Find articles by Li, W. in: JCI | PubMed | Google Scholar

Find articles by Shenkar, R. in: JCI | PubMed | Google Scholar

Find articles by Detter, M. in: JCI | PubMed | Google Scholar

Find articles by Moore, T. in: JCI | PubMed | Google Scholar

Find articles by Benavides, C. in: JCI | PubMed | Google Scholar

Find articles by Lightle, R. in: JCI | PubMed | Google Scholar

Find articles by Girard, R. in: JCI | PubMed | Google Scholar

Find articles by Hobson, N. in: JCI | PubMed | Google Scholar

Find articles by Cao, Y. in: JCI | PubMed | Google Scholar

Find articles by Li, Y. in: JCI | PubMed | Google Scholar

Find articles by Griffin, E. in: JCI | PubMed | Google Scholar

Find articles by Gallione, C. in: JCI | PubMed | Google Scholar

Find articles by Zabramski, J. in: JCI | PubMed | Google Scholar

Find articles by Ginsberg, M. in: JCI | PubMed | Google Scholar

Find articles by Marchuk, D. in: JCI | PubMed | Google Scholar

Find articles by Awad, I. in: JCI | PubMed | Google Scholar

Published October 1, 2021 - More info

Published in Volume 131, Issue 19 on October 1, 2021
J Clin Invest. 2021;131(19):e154909. https://doi.org/10.1172/JCI154909.
© 2021 American Society for Clinical Investigation
Published October 1, 2021 - Version history
View PDF

Related article:

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models
Wenqing Li, … , Douglas A. Marchuk, Issam A. Awad
Wenqing Li, … , Douglas A. Marchuk, Issam A. Awad
Concise Communication Vascular biology

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

  • Text
  • PDF
Abstract

Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its S(-) enantiomer dramatically reduced embryonic venous cavernomas in ccm2 mosaic zebrafish, whereas R-(+)-propranolol, lacking β antagonism, had no effect. Silencing of the β1, but not β2, adrenergic receptor mimicked the beneficial effects of propranolol in a zebrafish CCM model, as did the β1-selective antagonist metoprolol. Thus, propranolol ameliorated cavernous malformations by β1 adrenergic antagonism in zebrafish. Oral propranolol significantly reduced lesion burden in 2 chronic murine models of the exceptionally aggressive Pdcd10/Ccm3 form of CCM. Propranolol or other β1-selective antagonists may be beneficial in CCM disease.

Authors

Wenqing Li, Robert Shenkar, Mathew R. Detter, Thomas Moore, Christian Benavides, Rhonda Lightle, Romuald Girard, Nicholas Hobson, Ying Cao, Yan Li, Erin Griffin, Carol Gallione, Joseph M. Zabramski, Mark H. Ginsberg, Douglas A. Marchuk, Issam A. Awad

×

Original citation: J Clin Invest. 2021;131(3):e144893. https://doi.org/10.1172/JCI144893

Citation for this corrigendum: J Clin Invest. 2021;131(19):e154909. https://doi.org/10.1172/JCI154909

Following the publication of this article, the authors became aware that an incorrect panel was used for Figure 3B. The correct panel for Figure 3B is below, showing the change in heart rate when mice were challenged with isoproterenol in a murine model of cerebral cavernous malformation treated with vehicle or propranolol. The Figure 3 legend is amended as follows: ***P < 0.001, by 2-way repeated-measures ANOVA with a post hoc Tukey’s honest significant difference test. The authors have stated that this corrected panel does not affect the results or conclusions of the article.

The authors regret the error.

Footnotes

See the related article at Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models.

Version history
  • Version 1 (October 1, 2021): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts